B of A Securities Downgrades LianBio: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
B of A Securities has downgraded LianBio (NASDAQ:LIAN) from a previous rating to Underperform, with a new price target set at $3.00, down from $5.00. LianBio's shares are currently trading at $4.29, down 1.83% over the last 24 hours. The new price target suggests a potential decrease of 30.07% from the current share price. LianBio is a biopharmaceutical company focusing on developing medicines for unmet medical needs in various therapeutic areas.
January 03, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
B of A Securities downgraded LianBio to Underperform and reduced the price target from $5.00 to $3.00. The stock is currently trading at $4.29, indicating a potential drop if it moves towards the new target.
The downgrade by B of A Securities is a direct negative sentiment towards LianBio's stock, suggesting lower performance expectations. The significant reduction in the price target could lead to bearish investor sentiment in the short term, potentially causing a decrease in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100